Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering
- Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market
- The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes
- This is timely, given Lexaria’s resolve to double down on GLP-1 investigations for the 2024 calendar year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under Nasdaq rules – per share yielded approximately $3.6 million in gross proceeds. This was offered by the company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-262402), and it opens Lexaria to important new opportunities for the 2024 calendar year (https://nnw.fm/wns57 ).
Most notably, Lexaria intends to use the net proceeds from this offering for research and development (“R&D”) studies, and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year.
“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” noted Chris Bunka, Lexaria’s CEO (https://nnw.fm/Gn6W4 ).
In 2023, Lexaria laid down the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose of Rybelsus that had been processed with DehydraTECH (TM) processing technology enhancements.
“Frankly, the results surprised us with their level of positivity,” noted Mr. Bunka.
“It was found that DehydraTECH processing: delivered a statistically-significant higher proportion of the semaglutide, and did so more quickly (very typical of results for our technology); reduced the quantity and severity of unwanted side effects; and had a statistically-significant impact on blood sugar in general and much more effectively after eating a meal, than did Rybelsus,” he added.
These results inspired the confidence of Lexaria’s team. In addition, the FDA’s recognition of GLP-1 drugs, having offered approvals as recently as 2021 and 2022 due to its health benefits, incentivized Lexaria to double down on this specific study. Consequently, the $3.6 million could not have come at a better time. Mr. Bunka and the rest of Lexaria’s management are optimistic that with this focus, the team’s hard work will prove its worth this year.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market
- The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes
- This is timely, given Lexaria’s resolve to double down on GLP-1 investigations for the 2024 calendar year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under Nasdaq rules – per share yielded approximately $3.6 million in gross proceeds. This was offered by the company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-262402), and it opens Lexaria to important new opportunities for the 2024 calendar year (https://nnw.fm/wns57 ).
Most notably, Lexaria intends to use the net proceeds from this offering for research and development (“R&D”) studies, and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year.
“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” noted Chris Bunka, Lexaria’s CEO (https://nnw.fm/Gn6W4 ).
In 2023, Lexaria laid down the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose of Rybelsus that had been processed with DehydraTECH (TM) processing technology enhancements.
“Frankly, the results surprised us with their level of positivity,” noted Mr. Bunka.
“It was found that DehydraTECH processing: delivered a statistically-significant higher proportion of the semaglutide, and did so more quickly (very typical of results for our technology); reduced the quantity and severity of unwanted side effects; and had a statistically-significant impact on blood sugar in general and much more effectively after eating a meal, than did Rybelsus,” he added.
These results inspired the confidence of Lexaria’s team. In addition, the FDA’s recognition of GLP-1 drugs, having offered approvals as recently as 2021 and 2022 due to its health benefits, incentivized Lexaria to double down on this specific study. Consequently, the $3.6 million could not have come at a better time. Mr. Bunka and the rest of Lexaria’s management are optimistic that with this focus, the team’s hard work will prove its worth this year.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
